NCIt definition : A humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both the tumor-associated
antigen (TAA) human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2) and the
costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member
9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon
administration, nesfrotamig simultaneously targets and binds to HER2 expressed on
tumor cells and 4-1BB expressed on activated T-lymphocytes and natural killer (NK)
cells. This crosslinks HER2-expressing tumor cells and 4-1BB-expressing T-cells and
NK cells, and activates 4-1BB signaling locally in the tumor microenvironment (TME).
This results in cytotoxic T-cell co-stimulation and enhances T-lymphocyte-mediated
anti-tumor activity. Nesfrotamig also promotes the secretion of interferon-gamma (IFNg)
from T-cells, which leads to tumor cell lysis. In addition, the binding of nesfrotamig
to HER2 prevents HER2-mediated signaling. This inhibits the proliferation of HER2-expressing
tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated
with increased tumor cell proliferation. 4-1BB, a surface glycoprotein of the tumor
necrosis factor receptor superfamily, is an inducible costimulatory receptor that
plays a key role in T-cell proliferation, survival and cytolytic activity.;
UNII : 8YNA3QG3DS;
CAS number : 2966936-23-0;
Molecule name : ABL-105; YH 32367; YH-32367; ABL 105;
Semantic type(s)